Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population

This study tests a combination of three drugs — methotrexate, erlotinib, and celecoxib — in people with relapsed or metastatic oral cavity cancer (cancer in the mouth) who have already received first-line treatment. This is aimed at patients in rural areas of the Midwest United States who have limited access to standard clinical trials. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of relapsed or metastatic oral cavity cancer - You have already received or are unable to receive first-line immunotherapy or chemo-immunotherapy - Your blood counts, liver, and kidney function are adequate - You can swallow pills **You may NOT be eligible if...** - You are pregnant, breastfeeding, or not willing to use contraception - You have uncontrolled heart disease (e.g., recent heart attack, severe heart failure, abnormal heart rhythm) - You have active hepatitis B or C (with detectable viral load) - You have another active cancer requiring treatment - You have psychiatric conditions that would prevent study compliance Talk to your doctor to see if this trial is right for you.